HC Wainwright Issues Positive Forecast for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for Nektar Therapeutics in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst A. He now forecasts that the biopharmaceutical company will post earnings of ($1.68) per share for the quarter, up from their previous forecast of ($1.82). HC Wainwright currently has a “Buy” rating and a $185.00 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($9.71) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q3 2026 earnings at ($1.90) EPS, Q4 2026 earnings at ($2.50) EPS, FY2026 earnings at ($7.94) EPS, Q1 2027 earnings at ($2.55) EPS, Q2 2027 earnings at ($1.21) EPS, Q3 2027 earnings at ($2.72) EPS, Q4 2027 earnings at ($2.36) EPS, FY2027 earnings at ($8.86) EPS, FY2028 earnings at ($9.53) EPS, FY2029 earnings at ($6.33) EPS and FY2030 earnings at $1.57 EPS.

Other equities research analysts also recently issued research reports about the company. Piper Sandler increased their target price on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. BTIG Research boosted their price objective on Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research note on Monday, April 20th. B. Riley Financial reissued a “buy” rating and set a $150.00 price objective (up from $105.00) on shares of Nektar Therapeutics in a report on Monday, February 23rd. Citigroup upped their price target on Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Finally, Wedbush cut their price objective on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $149.63.

Nektar Therapeutics Trading Down 0.4%

NKTR opened at $78.43 on Wednesday. Nektar Therapeutics has a 12 month low of $7.99 and a 12 month high of $109.00. The company has a market cap of $2.65 billion, a PE ratio of -9.31 and a beta of 1.24. The company has a 50 day moving average of $78.05 and a 200 day moving average of $61.35.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The business had revenue of $10.86 million during the quarter, compared to analysts’ expectations of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.

Institutional Trading of Nektar Therapeutics

Several hedge funds have recently added to or reduced their stakes in NKTR. BNP Paribas Financial Markets grew its position in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the last quarter. KBC Group NV bought a new stake in Nektar Therapeutics in the first quarter valued at approximately $52,000. Headlands Technologies LLC purchased a new stake in shares of Nektar Therapeutics during the second quarter valued at approximately $65,000. Integrated Wealth Concepts LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth approximately $68,000. Finally, Quarry LP bought a new position in shares of Nektar Therapeutics in the fourth quarter worth approximately $85,000. 75.88% of the stock is owned by institutional investors.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares of the company’s stock, valued at $5,510,697. The trade was a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.